

CPTC-CHEK2-1 (CAB079963)

Uniprot ID: [O96017](#)

Protein name: CHK2_HUMAN

Full name: Serine/threonine-protein kinase Chk2

Tissue specificity: High expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.

Function: Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells. Promotes the CCAR2-SIRT1 association and is required for CCAR2-mediated SIRT1 inhibition (PubMed:25361978).

Subcellular location:

Unnamed:

Nucleus > PML body

Nucleus > Nucleoplasm

NOTE: Recruited into PML bodies together with TP53.

Isoform 12:

Nucleus

Isoform 2:

Nucleus

NOTE: Isoform 10 is present throughout the cell.

Isoform 4:

Nucleus

Isoform 7:

Nucleus


Isoform 9:

Nucleus

Protein existence: Experimental evidence at protein level


Comment:

Immunohistochemistry




IHC protocol:	HIER pH6, Dilution 1:600
IHC test staining:	Moderate to strong cytoplasmic positivity in immunecells. Remaining tissues were negative.
Literature conformance:	Partly consistent with extensive gene/protein characterization data
Literature significance:	
RNA consistency:	Mainly not consistent with RNA expression data
IHC Sibling similarity:	Other antibody shows partly similar IHC staining pattern
IHC fail comment:	ANTIBODY FAILED: Improbable subcellular location, Improbable histological location, Not consistent with RNA

Immunofluorescence



IF Overlay:	antibody (green), anti-tubuline (red) and DAPI (blue)
IF main location:	Cytosol - 12: Uncertain (auto) Vesicles - 12: Uncertain (auto) Nucleoplasm - 3: Supportive (auto)
IF additional location:	
IF Antibody score:	Failed IF
IF in HEK 293:	Negative
IF in Hep G2:	Negative
IF in U-2 OS:	Nucleoplasm Vesicles Cytosol

Western blot



WB Size markers (kDa):	250, 130, 100, 70, 55, 35, 25, 15, 10
WB Lanes:	Marker (1), RT4 (2), U-251 MG (3), Plasma (4), Liver (5), Tonsil (6)
WB Target weight (kDa):	14, 16, 16, 19, 23, 31, 33, 34, 50, 58, 58, 61, 61, 61, 65
WB Validation:	Supported (Single band corresponding to the predicted size in kDa (+/-20%.))